A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Alogliptin (Primary) ; Glibenclamide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2009 Results have been published in Diabetes, Obesity and Metabolism.
    • 01 Feb 2009 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met according to results published in Diabetes, Obesity and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top